Breaking News

Citigroup Profit Falls 96% on Costs to End Mortgage-Bond Probe
Tweet TWEET

RTI Biologics Schedules 2012 Fourth Quarter, Year End Earnings and Conference Call for February 7, 2013

  RTI Biologics Schedules 2012 Fourth Quarter, Year End Earnings and
  Conference Call for February 7, 2013

Business Wire

ALACHUA, Fla. -- January 31, 2013

RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and
other biologic implants, announced today that it plans to release financial
results from the fourth quarter and year end 2012 on Thursday, Feb. 7, 2013
prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss the
fourth quarter and year end 2012 results at 8:30 a.m. ET the same day. The
conference call can be accessed by dialing (877) 383-7419. The webcast can be
accessed through the investor section of RTI’s website at www.rtix.com. A
replay of the conference call will be available on the RTI website for one
month following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for
surgeries around the world with a commitment to advancing science, safety and
innovation. RTI prepares human donated tissue and animal tissue for
transplantation through extensive testing and screening and using proprietary
processes. These allograft and xenograft implants are used in orthopedic,
dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for
biologics – from being the first company to offer precision-tooled bone
implants and assembled technology to maximize each gift of donation, to
inventing validated sterilization processes that include viral inactivation
steps. The BioCleanse® Tissue Sterilization Process, the Tutoplast® Tissue
Sterilization Process and the Cancelle™ SP Demineralization Process have a
combined record of more than four million implants distributed with zero
incidence of implant-associated infection. These processes have been validated
by tissue type to inactivate or remove viruses, bacteria, fungi and spores
from the tissue while maintaining biocompatibility and functionality.

Contact:

RTI Biologics Inc.
Robert Jordheim
Chief Financial Officer
rjordheim@rtix.com
or
Jenny Highlander, APR
Corporate Communications
jhighlander@rtix.com
386-418-8888